Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) EBIT Margin (2023 - 2025)

Immunome filings provide 3 years of EBIT Margin readings, the most recent being 1157.61% for Q2 2025.

  • On a quarterly basis, EBIT Margin rose 53482.0% to 1157.61% in Q2 2025 year-over-year; TTM through Mar 2026 was 5947.9%, a 395359.0% decrease, with the full-year FY2025 number at 3228.83%, up 15354.0% from a year prior.
  • EBIT Margin hit 1157.61% in Q2 2025 for Immunome, up from 1525.5% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 129.96% in Q3 2023 to a low of 12857.05% in Q1 2024.
  • Median EBIT Margin over the past 3 years was 1608.96% (2025), compared with a mean of 2492.75%.
  • Biggest five-year swings in EBIT Margin: plummeted -1266792bps in 2024 and later skyrocketed 1133155bps in 2025.
  • Immunome's EBIT Margin stood at 2473.94% in 2023, then dropped by -22bps to 3030.31% in 2024, then surged by 62bps to 1157.61% in 2025.
  • The last three reported values for EBIT Margin were 1157.61% (Q2 2025), 1525.5% (Q1 2025), and 3030.31% (Q4 2024) per Business Quant data.